![ECOG-ACRIN logo[19516]275x75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
Immunotherapy
May 28, 2021
The EA8185 phase II trial is the first prospective study exclusively for patients with lymph node positive bladder cancer
March 31, 2021
This phase II study, led by Dr. Ahmad Tarhini, is testing neoadjuvant treatment with pembrolizumab alone versus pembrolizumab and an investigational drug called CMP-001
February 25, 2021
This three-arm phase II study, led by Dr. Dan Zandberg, is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
December 14, 2020
EA2174 will evaluate the role of perioperative immunotherapy for patients with esophageal or gastroesophageal junction adenocarcinoma